A synthetic peptide fragment of Thymosin Beta-4 — one of the most abundant proteins in mammalian cells — studied for its pivotal role in actin regulation, cell migration, and tissue repair signaling.
TB-500 is among the most directly impacted peptides in the current FDA regulatory cycle. Two significant events have occurred in 2026, with a third on the horizon.
Removal from Category 2 ≠ legalization of compounding. Category 2 removal ends an explicit prohibition; it does not place TB-500 on the affirmative 503A list that governs what compounding pharmacies may use. The PCAC hearing and subsequent FDA rulemaking are the remaining steps required before compounding would be legally authorized.
Political context: The MAHA movement and RFK Jr.'s elevated role at HHS have increased public attention to peptide access. The PCAC process is formal and evidence-based — political attention may accelerate timelines but does not substitute for the committee's independent evaluation or the rulemaking process that follows.
TB-500 remains Research Use Only on this platform regardless of compounding status. Regulatory changes to compounding pharmacy rules do not affect RUO research access.
📡 Weekly peptide research updates — regulatory updates, new compound profiles, COA alerts.
⚠️ FDA PCAC: -- days leftNo spam. Unsubscribe anytime. 7 peptides under review — see what's at stake →
TB-500 is a synthetic peptide derived from a specific region of Thymosin Beta-4 (Tβ4) — a small protein that is one of the most abundant molecules inside virtually every cell in your body. Thymosin Beta-4 is a 43-amino-acid protein that was first isolated from thymic tissue (hence the name), but researchers quickly discovered it's far more widespread than just immune tissue. It's found in high concentrations in platelets, wound fluid, and almost all nucleated cells.
The "TB-500" designation refers to a specific active fragment of the Thymosin Beta-4 molecule that is believed to retain the key biological activity while being easier to synthesize and study. The specific fragment that makes TB-500 is the LKKTETQ peptide sequence — a short actin-binding domain that does a lot of the heavy lifting in Tβ4's biological effects.
What drew researchers to Thymosin Beta-4 originally was its unusually high concentration at wound sites and in developing tissue. Wherever repair is happening in the body, Tβ4 tends to show up in elevated levels. That correlation sparked decades of research into what it's actually doing at those sites and whether synthetic versions could be useful research tools.
7 free research tools built around exactly this kind of compound data. No paywall, no credit card.
TB-500 / Thymosin Beta-4 has attracted significant research attention because it sits at a critical junction of several biological repair processes simultaneously:
TB-500's primary mechanism centers on actin dynamics. Inside every cell, actin exists in two forms: G-actin (free globular units) and F-actin (long polymerized filaments that form the cell's internal skeleton). TB-500 binds to G-actin monomers and sequesters them, which regulates the balance between these two forms. This is important because the cell's ability to change shape, move, and divide depends critically on controlling this balance.
Beyond actin regulation, TB-500 interacts with integrin signaling pathways, which govern how cells sense and interact with their surrounding tissue environment. It upregulates matrix metalloproteinases (enzymes that help clear damaged tissue) and promotes expression of VEGF, which drives new blood vessel formation into healing tissue. The result is a peptide that affects repair at multiple levels: cellular movement, structural remodeling, and vascular supply simultaneously.
Imagine cells as workers who need to physically walk across a construction site to do their jobs. TB-500 is like providing those workers with better shoes AND clearing the debris from their path. The "shoes" (actin regulation) help cells move more efficiently; the "path clearing" (ECM remodeling) removes the obstacles blocking cell migration to the damage site. Then it also calls in the water truck (VEGF/angiogenesis) to keep everything running.
Research Disclaimer: The following reflects published clinical and preclinical research and is not medical advice. Consult a licensed healthcare provider before making any health decisions.
Thymosin Beta-4 (TB-500's precursor peptide) has advanced to human clinical trials for cardiac and wound healing indications, providing relatively rare clinical dosing data for a research peptide. The following summarizes parameters from published preclinical and human research.
Thymosin Beta-4 in research settings is reconstituted from lyophilized form using bacteriostatic water or sterile saline. The RegeneRx clinical formulations (RGN-352 injectable) used standard pharmaceutical excipients for injectable preparations. Lyophilized TB-500/Tβ4 is documented stable at −20°C with protection from repeated freeze-thaw cycles. Solution stability at 4°C is generally cited as days to a few weeks — lyophilized storage preferred for longer durations.
The human cardiac trial used acute single-dose or short-course IV administration. Wound healing studies used intermittent injection protocols (twice-weekly in some protocols). Equine preclinical studies used once- to twice-weekly local injections over 4–12 weeks. No published research has established optimal injection frequency for systemic musculoskeletal research in humans — protocols varied significantly across published studies.
Key References: Sopko N et al. (2018). Cardiac Tβ4 trial LILAC. JACC: Basic Transl Sci. · Sosne G et al. (2010). Thymosin beta 4 corneal wound healing. Cornea. · Dahlgren LA et al. (2010). Tβ4 equine tendon repair. Equine Vet J. · Goldstein AL et al. (2012). Thymosin Beta-4 review. Ann NY Acad Sci.
TB-500 / Thymosin Beta-4 was studied in clinical trials for cardiac repair — specifically after heart attacks — making it one of the few peptides in this category to advance to human trials for a serious cardiac indication. That research is ongoing.
Thymosin Beta-4 is actually detected in equine (horse) blood and has appeared on prohibited substance lists for horse racing. This gave it an unexpected profile boost in sports science research communities who became curious about its mechanisms.
Tβ4 is one of the most abundant intracellular proteins in mammals — it makes up roughly 0.5% of total cellular protein in some cell types. Something this abundant clearly has important housekeeping functions beyond just wound repair.
Every batch of TB-500 with full Certificate of Analysis documentation. Third-party HPLC verification, mass spectrometry confirmation, and sterility testing results are included with each batch.